Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease

Annals of Allergy, Asthma and Immunology

Volumn 93, Issue 4, 2004, Pages 339-344

  Woessner, Katharine M ^a   Simon, Ronald A ^a   Stevenson, Donald D ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTAGLANDIN E2; ROFECOXIB; ZAFIRLUKAST;

ADULT; ARTICLE; ASPIRIN EXACERBATED RESPIRATORY DISEASE; ASTHMA; CROSS REACTION; DISEASE EXACERBATION; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROVOCATION TEST; RESPIRATORY TRACT DISEASE; SCORING SYSTEM; SINUSITIS; SYMPTOMATOLOGY;

EID: 6044254955     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61392-0     Document Type: Article

References (43)

1. Stevenson DD, Hankammer MA, Mathison DA, Christiansen SC, Simon RA. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes. J Allergy Clin Immunol. 1996;98:751-758.
2. Kowalski ML, Pawliczak R, Wozniak J, et al. Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients. Am J Respir Crit Care Med. 2000;161:391-398.
3. 4 release from activated neutrophils. Proc Natl Acad Sci USA. 1983;80:4349-4353.
4. Hogaboam CM, Bissonnette EY, Chin BC, Befus AD, Wallace JL. Prostaglandins inhibit inflammatory mediator release from rat mast cells. Gastroenterology. 1993;104:122-129.
5. 2: apparent correlation with in vivo modulation of mediator release. Proc Natl Acad Sci USA. 1988; 85:2315-2319.
6. 2 reverses indomethacin-induced enhancement of acute allergic inflammation in the hamster cheek pouch. Adv Prostaglandin Thromboxane Leukot Res. 1987;17B:908-912.
7. 2 prevents diclofenac-induced enhancement of histamine release and inflammation evoked by in vivo challenge with compound 48/80 in the hamster cheek pouch. Agents Actions. 1989;28: 108-114.
8. Raud J, Dahlen SE, Smedegard G, Hedqvist P. An intravital microscopic model for mast cell-dependent inflammation in the hamster cheek pouch. Acta Physiol Scand. 1989;135:95-105.
9. Raud J, Dahlen SE, Sydbom A, Lindbom L, Hedqvist P. Prostaglandin modulation of mast cell-dependent inflammation. Agents Actions. 1989;26:42-44.
10. 1) on aspirin-induced bronchoconstriction in aspirin-sensitive asthma. J Investig Allergol Clin Immunol. 1996;6:121-125.
11. Szczeklik A, Mastalerz L, Nizankowska E, Cmiel A. Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma. Am J Respir Crit Care Med. 1996;153: 567-571.
12. 4 excretion in aspirin-sensitive asthma. Am J Respir Crit Care Med. 1996; 153:572-575.
13. Sousa AR, Pfister R, Christie PE, et al. Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin-sensitive asthma. Thorax. 1997;52:940-945.
14. Stevenson DD, Sanches-Borges M, Szczeklik A. A classification of allergic and pseudoallergic reactions that inhibit cyclooxygenase enzymes. Ann Allergy Asthma Immunol. 2001;87: 166-170.
15. Hawkey CJ. COX-2 inhibitors. Lancet. 1999;353:307-314.
16. Quaratino D, Romano A, Di Fonso M, et al. Tolerability of meloxicam in patients with histories of adverse reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol. 2000;84:613-617.
17. Bavbek S, Celik G, Ediger D, Mungan D, Demirel YS, Misirligil Z. The use of nimesulide in patients with acetylsalicylic acid and nonsteroidal anti-inflammatory drug intolerance. J Asthma. 1999;36:657-663.
18. Senna GE, Passalacqua G, Andri G, et al. Nimesulide in the treatment of patients intolerant of aspirin and other NSAIDs. Drug Safety. 1996;14:94-103.
19. Bianco S, Robuschi M, Petrigni G, et al. Efficacy and tolerability of nimesulide in asthmatic patients intolerant to aspirin. Drugs. 1993;46(Suppl):115-120.
20. Quaratino D, Romano A, Papa G, et al. Long-term tolerability of nimesulide and acetaminophen in nonsteroidal antiinflammatory drug-intolerant patients. Ann Allergy Asthma Immunol. 1997;79:47-50.
21. West PM, Fernandez C. Safety of COX-2 inhibitors in asthma patients with aspirin hypersensitivity. Ann Pharmacother. 2003; 37:1497-1501.
22. Picado P. COX-2 specific inhibitors in NSAID-intolerant patients. Int J Immunopathol Pharmacol. 2003;16:11-16.
23. Martin-Garcia C, Hinojosa M, Berges P, Camacho E, Garcia-Rodriguez R, Alfaya T. Celecoxib, a highly selective COX-2 inhibitor, is safe in aspirin-induced asthma patients. J Investig Allergol Clin Immunol. 2003;13:20-25.
24. Gyllfors P, Bochenek G, Overholt J, et al. Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgesic drug celecoxib. J Allergy Clin Immunol. 2003;111:1116-1121.
25. Martin-Garcia C, Hinojosa M, Berges P, et al. Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma. Chest. 2002;121:1812-1817.
26. Marks F, Harrell K, Fischer R. Successful use of cyclooxygenase-2 inhibitor in a patient with aspirin-induced asthma. South Med J. 2001;94:256-257.
27. Perrone MR, Artesani MC, Viola M, et al. Tolerability of rofecoxib in patients with adverse reactions to nonsteroidal anti-inflammatory drugs: a study of 216 patients and literature review. Int Arch Allergy Immunol. 2003;132:82-86.
28. Valero A, Baltasar M, Enrique E, et al. NSAID-sensitive patients tolerate rofecoxib. Allergy. 2002;57:1214-1215.
29. Stevenson DD, Simon RA. Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. J Allergy Clin Immunol. 2001;108:47-51.
30. Szczeklik A, Nizankowska E, Bochenek G, Nagraba K, Mejza F, Swierczynska M. Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin Exp Allergy. 2001;31:219-225.
31. Woessner KM, Simon RA, Stevenson DD. The safety of celecoxib in patients with aspirin-sensitive asthma. Arthritis Rheum. 2002;46:2201-2206.
32. Dahlen B, Szczeklik A, Murray JJ. Celecoxib in patients with asthma and aspirin intolerance: the Celecoxib in Aspirin-Intolerant Asthma Study Group. N Engl J Med. 2001;344:142.
33. Dicpinigaitis PV. Effect of the cyclooxygenase-2 inhibitor celecoxib on bronchial responsiveness and cough reflex sensitivity in asthmatics. Pulm Pharmacol Ther. 2001;14:93-97.
34. Stevenson DD, Simon RA. Sensitivity to aspirin and nonsteroidal antiinflammatory drugs. In: Middleton RC, Ellis EF, Adkinson NF Jr, Yunginger JW, Busse WW, editors. Allergy: Principles and Practice. 5th ed. St Louis, MO: Mosby; 1998: 1225-1234.
35. Pauls JD, Simon RA, Daffern P, Stevenson DD. Effectiveness of the 5-LO inhibitor zileuton during oral challenges in aspirin-sensitive asthmatics. Ann Allergy Asthma Immunol. 2000;85: 40-45.
36. Lehman EL. Testing Statistical Hypotheses. New York, NY: John Wiley & Sons Inc; 1986.
37. Nizankowska E, Szczeklik A. Glucocorticosteroids attenuate aspirin-precipitated adverse reactions in aspirin-intolerant patients with asthma. Ann Allergy. 1989;63:159-162.
38. Stevenson DD, Simon RA, Christiansen SC. Lack of cross-reactivity between selective COX-2 inhibitors and aspirin (ASA) in ASA-sensitive asthmatics [abstract]. J Allergy Clin Immunol. 2000;105:8273.
39. Szczeklik A, Serwonnska M. Inhibition of idiosyncratic reactions to aspirin in asthmatic patients by clemastine. Thorax. 1979;34:654-659.
40. Grimm V, Rakoski J, Ring J. Urticaria and angioedema induced by COX-2 inhibitors [letter]. J Allergy Clin Immunol. 2002;109: 370.
41. Kelkar PS, Butterfield JH, Teaford HG. Urticaria and angioedema from cyclooxygenase-2 inhibitors. J Rheumatol. 2001; 28:2553-2554.
42. Schellenberg RR, Isserow SH. Anaphylactoid reaction to a cyclooxygenase-2 inhibitor in a patient who had a reaction to a cyclooxygenase-1 inhibitor [letter]. N Engl J Med. 2001;345:1856.
43. Sanchez Borges M, Capriles-Hulett A, Caballero-Fonseca F, Perez CR. Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions. Ann Allergy Asthma Immunol. 2001;87:201-204.